Advances in Our Understanding of the Interaction of Drugs with T-cells: Implications for the Discovery of Biomarkers in Severe Cutaneous Drug Reactions

Chem Res Toxicol. 2022 Jul 18;35(7):1162-1183. doi: 10.1021/acs.chemrestox.1c00434. Epub 2022 Jun 15.

Abstract

Drugs can activate different cells of the immune system and initiate an immune response that can lead to life-threatening diseases collectively known as severe cutaneous adverse reactions (SCARs). Antibiotics, anticonvulsants, and antiretrovirals are involved in the development of SCARs by the activation of αβ naïve T-cells. However, other subsets of lymphocytes known as nonconventional T-cells with a limited T-cell receptor repertoire and innate and adaptative functions also recognize drugs and drug-like molecules, but their role in the pathogenesis of SCARs has only just begun to be explored. Despite 30 years of advances in our understanding of the mechanisms in which drugs interact with T-cells and the pathways for tissue injury seen during T-cell activation, at present, the development of useful clinical biomarkers for SCARs or predictive preclinical in vitro assays that could identify immunogenic moieties during drug discovery is an unmet goal. Therefore, the present review focuses on (i) advances in the understanding of the pathogenesis of SCARs reactions, (ii) a description of the interaction of drugs with conventional and nonconventional T-cells, and (iii) the current state of soluble blood circulating biomarker candidates for SCARs.

Publication types

  • Review

MeSH terms

  • Anticonvulsants
  • Biomarkers / metabolism
  • Cicatrix / complications
  • Cicatrix / drug therapy
  • Cicatrix / pathology
  • Drug-Related Side Effects and Adverse Reactions / metabolism*
  • Humans
  • Skin / metabolism
  • Stevens-Johnson Syndrome / drug therapy
  • Stevens-Johnson Syndrome / etiology
  • Stevens-Johnson Syndrome / pathology
  • T-Lymphocytes*

Substances

  • Anticonvulsants
  • Biomarkers